Replies to post #150363 on Biotech Values

[DewDiligence]

The purpose of the GALA trial was to show that the thrice-weekly 40mg formulation's efficacy and safety are in the same ballpark as the 'known' profile of regular daily Copaxone, with emphasis on the convenience benefit.

I would submit that a thrice-weekly schedule is no great shakes when it comes to convenience due to the need for users to remember more information about which days are on and which days are off. Moreover, inasmuch as 7 is not divisible by 3, the dosing intervals cannot be equalized, which leads to less than optimal treatment from a PK standpoint.

Bottom line: I do expect thrice-weekly Copaxone to take some market share, but not a lot, and probably not until 2015 (see bottom of #msg-63817727). Thus, the timing issue you addressed in #msg-76619930 still pertains, IMO.